Teprotumumab-related Cutaneous Hypersensitivity Reactions

The authors report 4 cases of cutaneous hypersensitivity reactions developing in the course of teprotumumab treatment for thyroid eye disease. The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment. Here, we present 4 cases of cutaneous hypersensitivity reactions to teprotumumab, a previously unreported adverse effect in thyroid eye disease (TED) treatment.